FDA Approves Miplyffa for Treatment of Niemann-Pick Disease, Type C
Miplyffa is the first drug approved for treating associated neurological symptoms in adults and children 2 years and older
Aggressive, Early Disease-Modifying Therapy May Slow MS Progression
Development of paramagnetic rim lesions tied to more rapid disability progression
Vaping Tied to Lower Cognitive Scores in College Students
Significant interactions seen for inhalant usage patterns, including frequency and type
Cognitive Behavioral Therapy Program Aids Insomnia in Breast Cancer Survivors
Intervention includes six-week in-home, voice-activated cognitive behavioral therapy program
Adverse Brain Health Outcomes Increased for Sexual, Gender Minority Groups
Increased risk seen for a composite of stroke, dementia, late-life depression, which persisted for sexual, gender minorities separately
European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
Phase 3 data show efficacy and safety profile similar to intravenous administration
Prenatal Exposure to Pandemic Milieu, Maternal SARS-CoV-2 Does Not Increase Autism Risk
No increased rates of positive M-CHAT-R screening seen for offspring
Anti-CD20 Therapy Shows No Effect on Disability Progression in MS
Anti-CD20-treated primary progressive multiple sclerosis patients have higher risk for serious infection
Risk for Stroke, TIA Increased in Adults With Sickle Cell Disease
Cumulative incidence of first ischemic stroke was 2.1 percent by age 20 years, 13.5 percent by age 60 years
